SERF2

Across TCGA pan-cancer cohorts, SERF2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SERF2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SERF2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SERF2 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

LUAD, CCRCC, and LSCC are the cancer types where SERF2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SERF2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	+0.862	<.001	9	view →
CCRCC	Female	All	−0.186	<.001	9	view →
LSCC	Male	II,III,IV	+0.525	<.001	8	view →
COAD	All	II,III,IV	+0.192	<.001	8	view →
HNSC	Male	All	+0.211	<.001	7	view →
OV	All	All	+0.618	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SERF2–LUAD

Open the LUAD breakdown →